NERV · Minerva Neurosciences, Inc. · Executive Compensation
$3.40
+0.08 (+2.41%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$162.34M
Shares
47.75M
Volume · Oct 6
44.71K
Avg daily vol (3M)
187.53K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Anthony Aliquo | Chief Accounting Officer and principal accounting officer | Appointed | 2026-08-12 |
| Jim O'Connor | Chief Business Officer | Appointed | 2026-04-02 |
| James O'Connor | Chief Business Officer and General Counsel | Appointed | 2026-04-02 |
| Geoffrey Race | President | Resigned | 2026-04-02 |
| Inderjit Kaul | Director | Appointed | 2025-12-22 |
| Fouzia Laghrissi-Thode | Director | Appointed | 2025-12-22 |
| Inderjit Kaul | director | Appointed | 2025-11-19 |
| David Kupfer | member of the Audit Committee | Appointed | 2024-05-30 |
| Jan van Heek | Chair of the Audit Committee | Appointed | 2024-05-30 |
| Jeryl Hilleman | Chair of the Audit Committee of the Board | Resigned | 2024-05-30 |
| Jeryl Hilleman | member of the Board | Resigned | 2024-05-30 |
| Hans Peter Hasler | member of the Audit Committee | Appointed | 2023-05-05 |
| Fouzia Laghrissi-Thode, M.D. | Chair of the Compensation Committee | Appointed | 2023-05-05 |
| William Doyle | member of the Board | Resigned | 2023-05-05 |